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Materials and Methods: In vitro, we examined the effect of 
AT-101 (kindly provided by Ascenta Therapeutics Inc.) 
radiation and the combination on apoptosis induction and 
clonogenic survival in two HNSCC cell lines that expressed 
the target proteins: UM-SCC-11B (derived from a primary 
tumor of the larynx) and VU-SCC-OE (derived from a primary 
tumor of the oral cavity). Apoptosis was determined by bis-
benzimide staining to detect morphological nuclear changes 
and/or by propidium iodide staining and flow-cytometry 
analysis to quantify sub-diploid apoptotic nuclei. The type of 
interaction between AT-101 and radiation was evaluated by 
determining the Combination Index (CI) and isobolographic 
analysis. In addition, we assessed clonogenic survival upon 
combined treatment in the VU-SCC-OE cell line. In the 
clinical study, N07CRH, patients with locally advanced 
HNSCC, were enrolled in a two-arm trial design with standard 
radiotherapy/cisplatin treatment combined with concurrent 
dose-escalating oral AT-101 according to two different 
schedules, a 2-weeks daily schedule every 3 weeks, and a 
pulse-dose schedule on 3 consecutive days, every 3 weeks. 
Blood samples were collected and serum concentrations of 
AT-101 were determined by HPLC methods. 
Results: In vitro results showed that AT-101 (10-15 μM) 
enhances radiation(5Gy)-induced apoptosis with CI's ranging 
from 1.1 (additive) to 0.74 (synergistic). Clonogenic survival 
assays showed a radiosensitizing effect with a DEF37 of 1.3 at 
concentrations of AT-101 that were markedly lower than used 
for apoptosis studies. Patients tolerated AT-101 well up to 
doses of 20 mg. Pharmacokinetic analyses of blood samples 
taken from the patients at time intervals from 30 minutes up 
to 24 hours after oral intake showed a dose-dependent 
increase in serum concentration with peak concentrations up 
to 300 - 700 ng/ml (0.5 – 1.2 μM) between 2 and 2.5 hours 
after intake. 
Conclusions: AT-101 is a competent enhancer of radiation-
induced apoptosis in HNSCC in vitro. In addition, in vitro 
radiosensitization was observed at clinically achievable serum 
levels. These finding support further evaluation of the 
combination of AT-01 with radiation in Bcl-2-overexpressing 
tumors.  
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Purpose/Objective: Radiation therapy is a primary treatment 
modality for prostate cancer. Over activation of the 
phosphoinositide 3-kinase (PI3K) pathway causes 
radioresistance increasing cell survival following radiation, 
resulting in treatment failure and disease recurrence. 
Downstream effects of PI3K increase HIF1-α concentrations 
resulting in high levels of hypoxia in PI3K activated prostate 
cancer cells. This study investigated the effect of PI3K 
inhibitor, GDC-0941, on the radiosensitisation of cell lines 
DU145 and 22Rv1 under hypoxic and normoxic conditions. 
Materials and Methods: GDC-0941 was combined with 
radiation treatment to assess the radiosensitisation effect in 
DU145 and 22Rv1 cell lines. GDC-0941 was also tested under 
hypoxic conditions to assess if radiosensitivity was 
maintained. Clonogenic assays were used to assess cell 
survival under the varied treatment conditions. 
Results: GDC-0941 was shown to enhance radiosensitivity in 
both 22Rv1 (2Gy: SER=1.7, p=0.038) and DU145 (2Gy: SER=2, 
p=0.0025). The radiosensitisation conferred was also 
significant under hypoxic conditions in 22Rv1 (2Gy: SER=2, 
p=0.0155) although non-significant in DU145 (2Gy: SER=1.1, 
p=0.1835). GDC-0941 showed comparable radiosensitisation 
under both normoxic and hypoxic conditions in both cell 
lines. 
Conclusions: GDC-0941 radiosensitised prostate cancer cells 
under hypoxic and normoxic conditions. 
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Purpose/Objective: The anti-neoplastic compound Paclitaxel 
(Taxol®) is adopted for multiple strategies of cancer 
treatment encompassing classic chemotherapy on the one 
side as well as adjuvant treatment settings that combine 
chemotherapy with other treatment modalities like radiation 
therapy on the other. The molecular mechanism(s) by which 
Paclitaxel exerts radiosensitization of tumor cells is not 
understood in full detail. Moreover, the doses of Paclitaxel 
that are currently applied in the clinic often coincide with 
side effects of major severity. Finally, no stratification 
markers that allow for predicting the responsiveness of 
tumors towards treatment schedules involving Paclitaxel and 
radiotherapy are available thus far. 
Materials and Methods: Multiple concentrations of Paclitaxel 
were screened for respective effects on the viability and the 
proliferation of tumor cells. After identifying low nanomolar 
doses of Paclitaxel to impact tumor cell proliferation and – 
viability in a hitherto highly neglected manner, a cohort of 
tumor cell lines was screened for individual differences in 
susceptibility towards equivalent doses of Paclitaxel, either 
administered alone or in combination with irradiation. Based 
on this screen, a search for new stratification markers was 
performed.  
Results: We show that Paclitaxel at lower nanomolar 
concentrations effectively sensitizes tumor cells towards 
ionizing radiation by facilitating high-grade aneuploidization. 
At such concentrations, Paclitaxel renders the ordinary, 
bipartite mode of cell division into a highly non-equational, 
mainly tripartite one thereby facilitating huge levels of 
aneuploidization and this is frequently followed by a distinct 
kind of apoptotic cell death. We show that this effect can be 
correlated with Paclitaxel-dependent radiosensitization of 
tumor cells since cell lines that are resistant to it are 
sensitized to lesser extends. We also provide evidence that 
both, Paclitaxel-dependent aneuploidization and – 
radiosensitization of tumor cells correlate with the 
expression levels of AURKA and TPX2, two proteins involved 
in mitotic spindle assembly, since a knockdown of TPX2 not 
only rescues the bipartite mode of cell division in the 
presence of Paclitaxel but also diminishes the 
radiosensitization effect that is achieved by Paclitaxel.  
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Conclusions: Here we describe a novel, hitherto largely 
neglected mode of action exhibited by Paclitaxel. This effect 
potentially constitutes for both, Paclitaxel's cytostatic – as 
well as radiosensitizing propensity as revealed by our data 
and a recent report by Zasadil et al. (2014). Moreover, we 
identify TPX2, a potential stratification marker not only for 
combined-modality approaches involving Paclitaxel and 
radiotherapy but for Paclitaxel-based treatment regimens. 
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Purpose/Objective: Anti-Epidermal Growth Factor Receptor 
(EGFR) drugs include monoclonal antibodies and tyrosine 
kinase inhibitors (TKIs). We previously showed that gefitinib 
(an EGFR TKI) reduced the proliferating capacity of surviving 
cells after radiotherapy (RT) combined with 5-fluorouracil 
(Palumbo I et al. Int J Colorectal Dis 2014). The aim of this 
study was to compare the effect of ADZ8931 (a novel 
equipotent EGFR, HER2 and HER3 TKI), alone or combined 
with RT, with cetuximab (an anti EGFR monoclonal antibody) 
and gefitinib in the LoVo colorectal cancer cell line with a 
mild EGFR and a low ERBB2 and ERBB3 expression. 
Materials and Methods: LoVo cells were treated with 0.8 mM 
cetuximab, gefitinib and AZD8931 (alone for 5 consecutive 
days), with fractionated RT (2 Gy daily for 3 consecutive 
days), or with drugs in combination with RT (starting drugs 
administration 48 h before RT and continuing it for additional 
3 consecutive days, for a total of 5 days). After treatments, 
cell cycle and apoptosis were evaluated by cytofluorimetric 
analysis, and the clonogenic capacity by colony forming unit 
assay (counting and measuring colonies with ImageJ 
software). Results were evaluated 24h after the end of each 
treatment.  
Results: Our preliminary results showed that all drugs alone 
slightly increased the apoptotic rate and G1 and G2-M cell 
cycle phases and, accordingly, reduced the S phase. 
Interestingly, AZD 8931 induced a more marked reduction in 
the S phase (the most radioresistant cell cycle phase) 
compared with cetuximab and gefitinib. Regarding the 
clonogenic capacity, our data showed that cetuximab 
reduced colonies number and size by 25% and 50%, 
respectively, and gefitinib by 35% and 70%, respectively, 
compared to untreated cells. It is worth of notice that the 
novel AZD 8931 TKI decreased the colony-forming capacity, in 
number and size, by about 10% more than gefitinib. Exposure 
of cells to RT alone increased the apoptotic rate, enhanced 
G1 and G2-M cell cycle phases, and reduced colonies number 
and size by about 70%, compared with untreated cells. RT in 
combination with all the tested drugs potentiated the above 
reported observed changes, particularly with AZD8931.  
Conclusions: To our knowledge, this is the first study 
describing the effect of the novel equipotent EGFR, HER2 and 
HER3 TKI AZD8931 combined with RT. Our data show that 
AZD8931, most of all the other tested drugs, decreased the 
growth of LoVo cells. Since we found that AZD8931 markedly 
reduced the radioresistant S-phase is reasonable to assume 
that this drug might represent a potentially effective 
radiosensitizing agent, even in tumor cells expressing mild or 
low levels of EGFR or ERBB2, ERBB3, respectively. 
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Purpose/Objective: Peptide receptor radionuclide therapy 
(PRRT) with 90Y-DOTATOC (YD) and 177Lu-DOTATATE (LuD) has 
been shown to be effective against neuroendocrine tumors 
(NETs), with up to 35% response rate and acceptable toxicity 
profile. In the clinical history of NET patients (pts), external 
beam radiation therapy (EBRT) may be proposed, as adjuvant 
in oligometastatic disease or palliative for analgesic purpose. 
The aim of this study is to assess whether the two radiation 
therapies are compatible or arise questions about 
tolerability. 
Materials and Methods: Over 807 pts treated with PRRT 
(1997-2014) for metastatic NETs in our institute, 15% 
underwent also EBRT. Of these, 17 pts with dosimetry and 
clinical information for both therapies were selected. They 
were affected by primary tumor in pancreas (10) and ileum 
(3) NETs, intestine (1) and lung (3) carcinoids, and had 
multiple mets in liver (15), bone (9), lymph nodes (7) and 
lung (3). Fourteen pts received EBRT after PRRT, while 3 
before. In 8 cases EBRT was considered adjuvant (see figure) 
- while palliative for the remaining. Bone mets were 
irradiated by single post or ant-post fields. In case of 
oligometastases, stereotactic IMRT or RapidArc treatments 
were applied, and treatment plans optimized accounting for 
the dose received by the organs at risk (OARs) during PRRT. 
The absorbed dose on OARs and tumour (T) were assessed 
and toxicity explored (CTCAE v4 criteria). For PRRT, kidneys 
(K) and red marrow (RM) were the OARs; dose to the liver (L) 
was also evaluated. For EBRT the OARs depended on the T 
site. 
